VivoSeq
Oncology

Stomach Cancer

12

Pipeline Programs↗

11

Active Trials↗

7

Companies Involved↗

Stomach Cancer is an emerging landscape with 12 programs across 7 companies. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

44/100

Pipeline Velocity

30/100

Mech. Concentration

29/100

Completion Rate

84/100

Attrition Rate

11/100

Pipeline

Programs by Phase

Analysis

Modality Breakdown

12programs
Small molecule650%
Monoclonal antibody433%
Antibody–drug conjugate217%

Modality classified for 100% of 12 pipeline programs.

Analysis

Trial Status

36

clinical trials

Completed21 · 58%
Not yet recruiting5 · 14%
Terminated4 · 11%
Active, not recruiting3 · 8%
Recruiting3 · 8%

Clinical Trials

Trial Activity

36 trials

Exploring the Difference Between Gastric Cardia Cancer and Non-cardia Gastric Cancer Based on Multiomics
Recruiting·QQilu Hospital of Shandong University·N/A·NCT05812287·120 enrolled
Conventional Versus Stomach-Partitioning Gastrojejunostomy for Malignant Gastric Outlet Obstruction in Stage IV Gastric Cancer (GO-PART Study, KLASS 16)
Recruiting·GGyeongsang National University Hospital·Preclinical·NCT07749326·144 enrolled
A Phase II Platform Trial of Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer (Neo-VIKTORY)
Recruiting·—·Phase 2·NCT06630130·100 enrolled
Efficacy and Safety of Serplulimab Combined With Nab-paclitaxel and SOX as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction: A Multicenter Randomized Controlled Trial
Active, not recruiting·XXijing Hospital·Phase 2·NCT06576921·116 enrolled
Prospective Randomized Trial to Evaluate the Efficacy and Safety of Maxigesic Injection for Post-operative Pain Control in Patients Who Have Undergone Laparoscopic or Robotic Gastrectomy
Active, not recruiting·SSeoul National University Bundang Hospital·Phase 2·NCT07768514·90 enrolled
Validation of a Molecular Test for Risk-stratification of Patients With High-risk Intestinal Metaplasia (GCEP2 Study)
Active, not recruiting·NNational University Hospital, Singapore·N/A·NCT05782465·500 enrolled
Safety and Efficacy Evaluation of Single-Port Versus Multi-Port Robotic-Assisted Radical Distal Gastrectomy for Gastric Cancer: a Multicenter, Prospective, Open-Label, Randomized Controlled Trial
Not yet recruiting·FFirst Affiliated Hospital of Wenzhou Medical University·Preclinical·NCT07828899·212 enrolled
A Phase II Clinical Study of Irinotecan Liposome Combined With Fruquintinib and Sintilimab as Second-Line Therapy for PD-L1-Positive (CPS ≥ 1) Advanced Gastric Cancer
Not yet recruiting·CCancer Hospital Chinese Academy of Medical Science, Shenzhen Center·Phase 2·NCT07819019·20 enrolled
TRANScriptional Pathways Of Surgical Pain Modulated by Music Therapy Exposure (TRANSPOSE): A Single Arm Pilot Study
Not yet recruiting·CCase Comprehensive Cancer Center·Preclinical·NCT07653594·20 enrolled
A Phase IV, Multicenter, Double-blind, Randomized Controlled Trial to Evaluate the Superiority of Maxigesic® Over Standard Analgesia in Patients Undergoing Radical Gastrectomy
Not yet recruiting·YYonsei University·Approved·NCT07687394·160 enrolled
A Comparative Study of One-Click Autofocus Versus Segmented Focus Techniques Under Magnifying Endoscopy for Gastric Diseases: A Tandem Randomized Controlled Trial
Not yet recruiting·SShandong University·Preclinical·NCT07664813·93 enrolled
Hereditary Gastric Cancer Syndromes: An Integrated Genomic and Clinicopathologic Study of the Predisposition to Gastric Cancer
Completed·National Cancer Institute (NCI)·N/A·NCT03030404·733 enrolled
The Effect of Stress Balls on Nausea, Anxiety, and Fatigue in Patients With Stomach Cancer
Completed·YYuzuncu Yil University·Preclinical·NCT07540169·52 enrolled
DX-8951f in Treating Patients With Metastatic Stomach Cancer
Completed·Daiichi Sankyo logoDaiichi Sankyo·Phase 2·NCT00017212
Capecitabine and Oxaliplatin Adjuvant Study in Stomach Cancer
Completed·Sanofi logoSanofi·Phase 3·NCT00411229·1,035 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)